Olema Pharmaceuticals, INC. (OLMA) — 8-K Filings

8-K Filings (17)

• Olema Pharmaceuticals Files 8-K — Nov 19, 2025 Risk: low
  Olema Pharmaceuticals, Inc. filed an 8-K on November 19, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain spe
• 8-K Filing — Nov 18, 2025
• Olema Pharmaceuticals Files 8-K — Oct 20, 2025 Risk: low
  Olema Pharmaceuticals, Inc. filed an 8-K on October 20, 2025, reporting events that occurred on October 18, 2025. The filing primarily concerns Regulation FD di
• Olema Pharmaceuticals Files 8-K — Sep 2, 2025 Risk: low
  Olema Pharmaceuticals, Inc. filed an 8-K on September 2, 2025, reporting on other events and financial statements. The filing does not contain specific material
• Olema Pharmaceuticals Files 8-K on Shareholder Matters — Jun 13, 2025 Risk: low
  Olema Pharmaceuticals, Inc. filed an 8-K on June 13, 2025, reporting on matters submitted to a vote of security holders as of June 10, 2025. The filing details
• Olema Pharmaceuticals Files 8-K — Mar 5, 2025 Risk: low
  Olema Pharmaceuticals, Inc. filed an 8-K on March 5, 2025, to report information under Regulation FD and to file financial statements and exhibits. The filing d
• Olema Pharmaceuticals Files 8-K — Jan 13, 2025 Risk: low
  Olema Pharmaceuticals, Inc. filed an 8-K on January 13, 2025, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not co
• Olema Pharmaceuticals Files 8-K — Jan 10, 2025 Risk: low
  Olema Pharmaceuticals, Inc. filed an 8-K on January 10, 2025, reporting unregistered sales of equity securities and filing financial statements and exhibits. Th
• Merck to Acquire Olema Pharmaceuticals for $2.5 Billion — Dec 10, 2024 Risk: low
  Olema Pharmaceuticals, Inc. announced on December 9, 2024, that it has entered into a definitive agreement to be acquired by Merck & Co., Inc. for $2.5 billion
• Olema Pharmaceuticals Enters Material Agreement, Discloses Equity Sales — Dec 2, 2024 Risk: medium
  Olema Pharmaceuticals, Inc. announced on November 29, 2024, that it entered into a material definitive agreement. The company also disclosed unregistered sales
• Olema Pharmaceuticals Files 8-K — Sep 27, 2024 Risk: low
  Olema Pharmaceuticals, Inc. filed an 8-K on September 27, 2024, to report on other events and financial statements. The filing does not contain specific details
• Olema Pharmaceuticals Files 8-K — Aug 6, 2024 Risk: low
  Olema Pharmaceuticals, Inc. filed an 8-K on August 6, 2024, reporting results of operations and financial condition, as well as financial statements and exhibit
• Olema Pharmaceuticals Enters Material Agreement — Jul 2, 2024 Risk: medium
  Olema Pharmaceuticals, Inc. entered into a material definitive agreement on June 28, 2024, which also created a direct financial obligation or an obligation und
• Olema Pharma Sets 2024 Annual Meeting Date — Jun 14, 2024 Risk: low
  Olema Pharmaceuticals, Inc. announced on June 13, 2024, that it will hold its 2024 Annual Meeting of Stockholders on July 25, 2024. The meeting will include the
• Merck to Acquire Olema Pharmaceuticals for $2.1 Billion — May 15, 2024 Risk: medium
  Olema Pharmaceuticals, Inc. announced on May 15, 2024, that it has entered into a definitive agreement to be acquired by Merck & Co., Inc. for $2.1 billion in c
• Olema Pharma Files Routine 8-K, Confirms Nasdaq Listing — Jan 8, 2024
  Olema Pharmaceuticals, Inc. filed an 8-K on January 8, 2024, to disclose general corporate information and confirm its status as a publicly traded company on Th
• Olema Pharma Files 8-K on Material Definitive Agreement — Jan 5, 2024
  Olema Pharmaceuticals, Inc. filed an 8-K on January 5, 2024, to report an "Entry into a Material Definitive Agreement" and "Other Events." This filing indicates

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX